Skip to main content

Advertisement

SpringerLink
Log in

Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Many people being treated for opioid use disorder continue to use drugs during treatment. This use occurs in patterns that rarely conform to well-defined cycles of abstinence and relapse. Systematic identification and evaluation of these patterns could enhance analysis of clinical trials and provide insight into drug use.

Objectives

To evaluate such an approach, we analyzed patterns of opioid and cocaine use from three randomized clinical trials of contingency management in methadone-treated participants.

Methods

Sequences of drug test results were analyzed with unsupervised machine-learning techniques, including hierarchical clustering of categorical results (i.e., whether any samples were positive during each week) and K-means longitudinal clustering of quantitative results (i.e., the proportion positive each week). The sensitivity of cluster membership as an experimental outcome was assessed based on the effects of contingency management. External validation of clusters was based on drug craving and other symptoms of substance use disorder.

Results

In each clinical trial, we identified four clusters of use patterns, which can be described as opioid use, cocaine use, dual use (opioid and cocaine), and partial/complete abstinence. Different clustering techniques produced substantially similar classifications of individual participants, with strong above-chance agreement. Contingency management increased membership in clusters with lower levels of drug use and fewer symptoms of substance use disorder.

Conclusions

Cluster analysis provides person-level output that is more interpretable and actionable than traditional outcome measures, providing a concrete answer to the question of what clinicians can tell patients about the success rates of new treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Anderlucci L, Hennig C (2014) The clustering of categorical data: a comparison of a model-based and a distance-based approach. Commun Stat - Theory Methods 43:704–721

    Google Scholar 

  • Bart G (2012) Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 31:207–225

    PubMed  PubMed Central  Google Scholar 

  • Carroll KM, Kiluk BD, Nich C, DeVito EE, Decker S, LaPaglia D, Duffey D, Babuscio TA, Ball SA (2014) Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. Drug Alcohol Depend 137:3–19

    PubMed  PubMed Central  Google Scholar 

  • Caudy MS, Tang L, Wooditch A, Taxman FS (2014) Short-term trajectories of substance use in a sample of drug-involved probationers. J Subst Abus Treat 46:202–213

    Google Scholar 

  • Center for Drug Evaluation and Research (2018) Opioid use disorder: endpoints for demonstrating effectiveness of drugs for medication-assisted treatment -- guidance for industry. Food and Drug Administration, US Department of Health and Human Services

  • DeSantis SM, Bandyopadhyay D (2011) Hidden Markov models for zero-inflated Poisson counts with an application to substance use. Stat Med 30:1678–1694

    PubMed  PubMed Central  Google Scholar 

  • DeSantis SM, Bandyopadhyay D, Back SE, Brady KT (2009) Non-treatment laboratory stress- and cue-reactivity studies are associated with decreased substance use among drug-dependent individuals. Drug Alcohol Depend 105:227–233

    PubMed  PubMed Central  Google Scholar 

  • Dobler-Mikola A, Hattenschwiler J, Meili D, Beck T, Boni E, Modestin J (2005) Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment. J Subst Abus Treat 29:259–265

    Google Scholar 

  • Dong H, Hayashi K, Singer J, Milloy MJ, DeBeck K, Wood E, Kerr T (2019) Trajectories of injection drug use among people who use drugs in Vancouver, Canada, 1996-2017: growth mixture modeling using data from prospective cohort studies. Addiction 114:2173–2186

    PubMed  Google Scholar 

  • Donovan DM, Bigelow GE, Brigham GS, Carroll KM, Cohen AJ, Gardin JG, Hamilton JA, Huestis MA, Hughes JR, Lindblad R, Marlatt GA, Preston KL, Selzer JA, Somoza EC, Wakim PG, Wells EA (2012) Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction 107:694–708

    PubMed  Google Scholar 

  • Epstein DH, Hawkins WE, Covi L, Umbricht A, Preston KL (2003) Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. Psychol Addict Behav 17:73–82

    PubMed  PubMed Central  Google Scholar 

  • Epstein DH, Schmittner J, Umbricht A, Schroeder JR, Moolchan ET, Preston KL (2009) Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug Alcohol Depend 101:92–100

    PubMed  Google Scholar 

  • Epstein DH, Heilig M, Shaham Y (2018) Science-based actions can help address the opioid crisis. Trends Pharmacol Sci 39:911–916

    CAS  PubMed  Google Scholar 

  • Gabadinho A, Ritschard G, Müller NS, Studer M (2011) Analyzing and visualizing state sequences in R with TraMineR. J Stat Softw 40:1–37

    Google Scholar 

  • Gardner RA, Epstein DH, Preston KL, Phillips KA (2019) Defining and predicting opioid and cocaine treatment response. Subst Use Misuse:1–10

  • Genberg BL, Gange SJ, Go VF, Celentano DD, Kirk GD, Mehta SH (2011) Trajectories of injection drug use over 20 years (1988-2008) in Baltimore, Maryland. Am J Epidemiol 173:829–836

    PubMed  PubMed Central  Google Scholar 

  • Genolini C, Alacoque X, Sentenac M, Arnaud C (2015) kml and kml3d: R packages to cluster longitudinal data. 2015 65: 34

  • Gossop M, Green L, Phillips G, Bradley B (1989) Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry J Ment Sci 154:348–353

    CAS  Google Scholar 

  • Gottheil E, Sterling RC, Weinstein SP (1993) Diminished illicit drug use as a consequence of long-term methadone maintenance. J Addict Dis 12:45–57

    CAS  PubMed  Google Scholar 

  • Hammon A, Zinn S (2020) Multiple imputation of binary multilevel missing not at random data. J R Stat Soc: Ser C: Appl Stat 69:547–564

    Google Scholar 

  • Hastie T, Tibshirani R, Friedman J (2017) Unsupervised learning. In: Diggle P, Gather U, Zeger S (eds) The elements of statistical learning: data mining, inference, and prediction. Springer, New York, pp 485–585

    Google Scholar 

  • Hedeker D, Mermelstein RJ, Demirtas H (2007) Analysis of binary outcomes with missing data: missing = smoking, last observation carried forward, and a little multiple imputation. Addiction 102:1564–1573

    PubMed  Google Scholar 

  • Hser YI, Huang D, Chou CP, Anglin MD (2007) Trajectories of heroin addiction: growth mixture modeling results based on a 33-year follow-up study. Eval Rev 31:548–563

    PubMed  Google Scholar 

  • Hser YI, Huang D, Brecht ML, Li L, Evans E (2008) Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis 27:13–21

    PubMed  PubMed Central  Google Scholar 

  • Hser YI, Huang D, Saxon AJ, Woody G, Moskowitz AL, Matthews AG, Ling W (2017) Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine + naloxone and methadone. J Addict Med 11:63–69

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jackson D, White IR, Mason D, Sutton S (2014) A general method for handling missing binary outcome data in randomized controlled trials. Addiction 109:1986–1993

    PubMed  PubMed Central  Google Scholar 

  • James G, Witten D, Hastie T, Tibshirani R (2013) Unsupervised learning. In: Casella G, Fienberg S, Olkin I (eds) An introduction to statistical learning – with applications in R. Springer, New York, pp 373–418

    Google Scholar 

  • Jones BL, Nagin DS, Roeder K (2001) A SAS Procedure Based on Mixture Models for Estimating Developmental Trajectories. Sociol Methods Res:29

  • Kennedy AP, Phillips KA, Epstein DH, Reamer DA, Schmittner J, Preston KL (2013) A randomized investigation of methadone doses at or over 100 mg/day, combined with contingency management. Drug Alcohol Depend 130:77–84

    CAS  PubMed  Google Scholar 

  • Kiluk BD, Fitzmaurice GM, Strain EC, Weiss RD (2019) What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning? Addiction 114:9–15

    PubMed  Google Scholar 

  • Lanza ST, Patrick ME, Maggs JL (2010) Latent transition analysis: benefits of a latent variable approach to modeling transitions in substance use. J Drug Issues 40:93–120

    PubMed  PubMed Central  Google Scholar 

  • Liu LC, Hedeker D, Segawa E, Flay BR (2010) Evaluation of longitudinal intervention effects: an example of latent growth mixture models for ordinal drug-use outcomes. J Drug Issues 40:27–44

    Google Scholar 

  • Maechler M, Rousseeuw P, Struyf A, Hubert M, Hornik K (2018) Cluster: cluster analysis basics and extensions, R package version 2.0.7–1

  • Magura S, Kang SY, Nwakeze PC, Demsky S (1998) Temporal patterns of heroin and cocaine use among methadone patients. Subst Use Misuse 33:2441–2467

    CAS  PubMed  Google Scholar 

  • Marsden J, Tai B, Ali R, Hu L, Rush AJ, Volkow N (2019) Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective? Addiction 114:1346–1353

    PubMed  PubMed Central  Google Scholar 

  • Maruotti A, Rocci R (2012) A mixed non-homogeneous hidden Markov model for categorical data, with application to alcohol consumption. Stat Med 31:871–886

    PubMed  Google Scholar 

  • Mattick RP, Breen C, Kimber J, Davoli M (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev Cd002207

  • McCann DJ, Ramey T, Skolnick P (2015) Outcome measures in medication trials for substance use disorders. Curr Treat Options Psychiatry 2:113–121

    Google Scholar 

  • McVicar D, Anydike-Danes M (2002) Predicting successful and unsuccessful transitions from school to work by using sequence methods. J R Stat Soc A 165:317–334

    Google Scholar 

  • Miele GM, Carpenter KM, Smith Cockerham M, Trautman KD, Blaine J, Hasin DS (2000) Substance Dependence Severity Scale (SDSS): reliability and validity of a clinician-administered interview for DSM-IV substance use disorders. Drug Alcohol Depend 59:63–75

    CAS  PubMed  Google Scholar 

  • Mikolajczyk RT, Horn J, Prins M, Wiessing L, Kretzschmar M (2014) Trajectories of injecting behavior in the Amsterdam cohort study among drug users. Drug Alcohol Depend 144:141–147

    PubMed  Google Scholar 

  • Milligan GW, Cooper MC (1987) Methodology review: clustering methods. Appl Psychol Meas 11:329–354

    Google Scholar 

  • Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O'Grady KE, Olsen YK, Jaffe JH (2015) Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use. J Psychoactive Drugs 47:149–157

    PubMed  PubMed Central  Google Scholar 

  • Nagin DS, Odgers CL (2010) Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 6:109–138

    PubMed  Google Scholar 

  • Petry NM, Alessi SM, Marx J, Austin M, Tardif M (2005) Vouchers versus prizes: contingency management treatment of substance abusers in community settings. J Consult Clin Psychol 73:1005–1014

    PubMed  Google Scholar 

  • Pinheiro J, Bates D, DebRoy S, Sarkar D (2019) Linear and nonlinear mixed effects models, R package version 3.1–143

  • R Core Team (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna

    Google Scholar 

  • Salsitz E, Wiegand T (2016) Pharmacotherapy of opioid addiction: “putting a real face on a false demon”. J Med Toxicol Off J Am Coll Med Toxicol 12:58–63

    CAS  Google Scholar 

  • Shirley KE, Small DS, Lynch KG, Maisto SA, Oslin DW (2010) Hidden Markov models for alcoholism treatment trial data. Ann Appl Stat 4:366–395

    Google Scholar 

  • Stitzer ML, Iguchi MY, Kidorf M, Bigelow GE (1993) Contingency management in methadone treatment: the case for positive incentives. NIDA Res Monogr Ser 137

  • Studer M, Ritschard G (2016) What matters in differences between life trajectories: a comparative review of sequence dissimilarity measures. J R Stat Soc Ser A (Stat Soc) 179:481–511

    Google Scholar 

  • Stull SW, Panlilio LV, Moran LM, Schroeder JR, Bertz JW, Epstein DH, Preston KL, Phillips KA (2019) The chippers, the quitters, and the highly symptomatic: a 12-month longitudinal study of DSM-5 opioid- and cocaine-use problems in a community sample. Addict Behav 96:183–191

    PubMed  PubMed Central  Google Scholar 

  • Sun J, Bi J, Chan G, Oslin D, Farrer L, Gelernter J, Kranzler HR (2012) Improved methods to identify stable, highly heritable subtypes of opioid use and related behaviors. Addict Behav 37:1138–1144

    PubMed  PubMed Central  Google Scholar 

  • Termorshuizen F, Krol A, Prins M, Geskus R, van den Brink W, van Ameijden EJ (2005) Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam cohort study among drug users. Drug Alcohol Depend 79:231–240

    PubMed  Google Scholar 

  • Venables WN, Ripley BD (2002) Modern applied statistics with S. Springer

  • Volkow ND, Frieden TR, Hyde PS, Cha SS (2014) Medication-assisted therapies--tackling the opioid-overdose epidemic. N Engl J Med 370:2063–2066

    PubMed  Google Scholar 

  • Volkow ND, Woodcock J, Compton WM, Throckmorton DC, Skolnick P, Hertz S, Wargo EM (2018) Medication development in opioid addiction: meaningful clinical end points. Sci Transl Med 10:eaan2595

    PubMed  Google Scholar 

  • Walker R (2009) Retention in treatment--indicator or illusion: an essay. Subst Use Misuse 44:18–27

    PubMed  Google Scholar 

  • Wang J (2014) Mixture modeling: a useful analytical approach for drug use studies. J Subst Abus Alcohol 2:1009–1010

    Google Scholar 

  • Wickham H (2009) ggplot2: elegant graphics for data analysis. Springer, New York

    Google Scholar 

  • Wojciechowski TW (2019) Developmental trajectories of opioid use among juvenile offenders: an epidemiological examination of group characteristics and criminological risk factors. Subst Use Misuse 54:1203–1213

    PubMed  Google Scholar 

  • Zhang Y, Luo X, Le CT, Ahluwalia JS, Thomas JL (2018) Analysis of self-report and biochemically verified tobacco abstinence outcomes with missing data: a sensitivity analysis using two-stage imputation. BMC Med Res Methodol 18:170

    PubMed  PubMed Central  Google Scholar 

  • Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI (2018) Correlates of long-term opioid abstinence after randomization to methadone versus buprenorphine/naloxone in a multi-site trial. J Neuroimmune Pharmacol 13:488–497

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by the Intramural Research Program of NIH, NIDA.

Author information

Authors and Affiliations

  1. Intramural Research Program, National Institute on Drug Abuse, 251 Bayview Blvd., Suite 200, Baltimore, MD, 21224, USA

    Leigh V. Panlilio, Samuel W. Stull, Jeremiah W. Bertz, Albert J. Burgess-Hull, William J. Kowalczyk, Karran A. Phillips, David H. Epstein & Kenzie L. Preston

  2. Department of Psychology, Hartwick College, Oneonta, NY, 13820, USA

    William J. Kowalczyk

Authors
  1. Leigh V. Panlilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel W. Stull
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeremiah W. Bertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albert J. Burgess-Hull
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William J. Kowalczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Karran A. Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David H. Epstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenzie L. Preston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leigh V. Panlilio.

Ethics declarations

All experiments were performed in accordance with protocols approved by the Addictions Institutional Review Board of the National Institutes of Health. All participants gave informed consent, and the privacy of participants is protected by a Certificate of Confidentiality from the Department of Health and Human Services, limiting the disclosure of identifiable, sensitive information.

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(PDF 785 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panlilio, L.V., Stull, S.W., Bertz, J.W. et al. Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials. Psychopharmacology 237, 3369–3381 (2020). https://doi.org/10.1007/s00213-020-05618-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-020-05618-5

Keywords

Search

Navigation